Allergic Diseases
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Longbio PharmaLP-003 Dose 1
Allergy TherapeuticsSystems Biology of Early Atopy
Clinical Trials (2)
Total enrollment: 2,506 patients across 2 trials
A Study of Single Dose of LP-003 in Adolescent Subjects
Start: Oct 2025Est. completion: Sep 20266 patients
Phase 1/2Active Not Recruiting
Systems Biology of Early Atopy
Start: Mar 2021Est. completion: Mar 20322,500 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.